Diabetes device manufacturers focus on China and India

NEW YORK – A new report from healthcare industry specialists GBI Research show that international medical companies are focusing on emerging countries such as India and China due to huge diabetes patient pools and comparatively low disease awareness in these countries.

According to the GBI Research report, big firms such as Roche, Sanofi, Novo Nordisk, and Lilly are increasing sales and marketing focus in these countries to tap the vast potential they hold in the global diabetes devices market.

In 2011, the Chinese diabetes devices market was valued at $776.2 million, with a projected Compound Annual Growth Rate (CAGR) of 5.9% to reach $1,161.1 million in 2018. An important driver for the national diabetes devices market is the Chinese government’s campaign to increase awareness of diabetes and spread the availability of treatment through schemes such as the National Diabetes Management Project.

GBI Research predicts an even more impressive expansion in India. The diabetes devices market was worth $146.5 million in 2011. This is projected to climb at a CAGR of 10% to a value of $285.2 million in 2018. Vast potential is seen in India since it is home to the second highest population of diabetes sufferers in the world, after China. In 2011, over 61 million people in India suffer from diabetes, with a projected increase to more than 101 million by 2030.